gms | German Medical Science

51. Kongress der Deutschen Gesellschaft für Handchirurgie

Deutsche Gesellschaft für Handchirurgie

07.10.- 09.10.2010, Nürnberg

Concurrent inhibition of TGF- and MAP kinase pathways lead to abrogated fibrotic traits of Dupuytren’s disease fibroblasts

Meeting Abstract

  • corresponding author presenting/speaker Carola Krause - Leiden University Medical Center, Molecular Cell Biology, Signal Transduction, Leiden, Niederlande
  • Peter Kloen
  • Christian Krause
  • Erik de Vink
  • Petra Knaus
  • Peter ten Dijke

Deutsche Gesellschaft für Handchirurgie. 51. Kongress der Deutschen Gesellschaft für Handchirurgie. Nürnberg, 07.-09.10.2010. Düsseldorf: German Medical Science GMS Publishing House; 2010. Doc10dgh06

doi: 10.3205/10dgh06, urn:nbn:de:0183-10dgh066

Published: September 16, 2010

© 2010 Krause et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Fragestellung: Which signaling pathways drive the fibro-proliferation of Dupuytren’s disease? Do chemical compounds that selectively inhibit these pathways give raise for possible non-surgical treatment strategies?

Methodik: Immunohistochemistry, Immunofluorescence, primary cell culture, reporter assay, fibroblast lattice contraction assay, mRNA and protein expression, bioinformatics based network modulation

Ergebnisse: We found that Dupuytrens’s fibroblasts in diseased tissues and cultured in vitro demonstrated increased TGF expression compared to control fibroblasts. Importantly, this correlated not only with elevated expression and activation of downstream Smad effectors, but also with overactive ERK1/2 MAP kinase signaling driven mainly through platelet-derived growth factors (PDGF). Both TGF/Smad and non-Smad signaling pathways were found to contribute to increased expression of key fibrotic markers and elevated contractility of Dupuytrens’s fibroblasts in a collagen lattice compared to control fibroblasts. Treatment with the TGF type I receptor kinase inhibitor SB-431542 and the ERK1/2 MAP kinase inhibitor PD98059 inhibited the increased contraction rate of Dupuytrens’s fibroblasts. Co-treatment of Dupuytrens’s fibroblasts with SB-431542 and PD98059 was sufficient for nearly complete inhibition of the contraction of Dupuytren’s disease fibroblasts, whereas the application of the PDGF receptor kinase inhibitor alone was not sufficient to abrogate contractility and extracellular matrix protein production. Furthermore we observed that TGF directly drives short term activation of ERK1/2 and additionally strongly promotes the expression of PDGF in Dupuytrens’s fibroblasts. Thus, we raised the question whether TGF signaling, in particular the short-term activation of ERK1/2 could lead to an autonomous non-Smad driven fibrotic stage. By modeling the TGF and PDGF network using a bioinformatics approach, we explored possible scenarios in which such a drift from Smad to autonomous non-Smad signaling can be observed.

Schlussfolgerung: All together our findings strongly suggest that usage of TGF and MAP kinase inhibitors abrogates fibrotic traits of Dupuytren’s disease which provides possible new directions for non-surgical intervention of Dupuytren’s disease.